STVN
T2Stevanato Group S.p.A.
OverviewStevanato Group S.p.A. provides integrated solutions for pharma and healthcare. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, the primary revenu
Stevanato Group S.p.A. provides integrated solutions for pharma and healthcare. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, the primary revenue driver (91% of Q1 2026 revenue), offers drug containment and delivery systems like syringes and vials, with high-value solutions making up 47% of total revenue, driven by biologics and GLP-1s (21-22% of Q1 2026 revenue). The Engineering segment supplies specialized machinery. They serve a global customer base of pharmaceutical and biotech companies.
- What They Do (Plain English & Analogies)
- Stevanato Group is like a specialized toolkit provider for pharmaceutical companies. Imagine drug manufacturers need to put their medicines into very specific, high-quality containers (like tiny glass vials, syringes, or cartridges) and sometimes also need the devices to inject them (like auto-injectors or pen injectors). Stevanato Group makes these containers and injection devices. They also build the highly precise machines that pharmaceutical companies use to make, inspect, assemble, and package these containers and devices themselves. So, they offer both the 'packaging' and 'delivery tools' for drugs, especially complex injectable medicines like biologics, and the 'factory equipment' to produce them. They are mission-critical to the delivery of biologics, supporting new therapeutic areas, expanding global access to treatments, and improving standards of care.
- Very Brief History
- Founded in 1949 by Giovanni Stevanato as Soffieria Stella, a handmade glass laboratory in Zelarino, Italy, the company initially produced glass bottles. In 1959, it moved to Piombino Dese and later established Ompi in 1969, specializing in pharmaceutical glass packaging. A key milestone was the founding of SPAMI in 1971, which focused on designing and building high-speed precision machinery for glass tube containers, creating an integrated model. The company expanded internationally through acquisitions and greenfield projects, launching its pre-sterilized EZ-fill® syringes in 2007 and going public on the NYSE in 2021 under the ticker STVN.
- "Street Stereotype"
- Stevanato Group is generally perceived by investors and analysts as a 'picks and shovels' play on the growth of injectable drugs, particularly biologics and self-administered medicines. The market views it as a high-quality, family-influenced business with a strong competitive position in high-precision pharmaceutical packaging. There's a focus on its integrated model (providing both containment/delivery solutions and the machinery to produce them) as a key competitive advantage. However, there are also concerns regarding the slower-than-anticipated turnaround of its Engineering segment and potential impacts from the rise of oral GLP-1 therapies on its injectable-focused business. Analyst consensus is a 'Moderate Buy'.
- Subsidiaries On Linked In*
- Ompi — Division/brand of Stevanato Group
- Balda — Division/brand of Stevanato Group (plastics solutions)
- Spami — Division/brand of Stevanato Group (Engineering Systems)
- Optrel — Division/brand of Stevanato Group (Engineering Systems)
- InnoScan — Division/brand of Stevanato Group (Engineering Systems)
- SVM — Division/brand of Stevanato Group (Engineering Systems)
- Customer Sectors & Example Clients
- Stevanato Group's customers are primarily in the pharmaceutical, biotechnology, and life sciences industries. They serve companies developing and manufacturing small molecules, highly sensitive drugs, vaccines, RNA-based drugs, GLP-1 and peptides, and monoclonal antibodies (mAbs) and Antibody-Drug Conjugates (ADCs). While specific client names are not explicitly stated, the company mentions working with 'big international clients,' 'bio customer,' and a 'leading manufacturer for use with a GLP-1 biosimilar for type 2 diabetes.' Given their market position and product focus, it's highly probable their clients include major global pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) such as Eli Lilly and Novo Nordisk (for GLP-1s), and other top-tier biotech firms.
- New Customers / Segments They'Re Targeting
- Stevanato Group is targeting new originators in clinical phases and biosimilars gaining traction in the GLP-1 market. They are also seeing demand for cartridges extending into many other traditional large pharma and emerging biotech players for biologics, including large volumes up to 20 ml for home-based subcutaneous injections. Additionally, the company recently launched a new service offering for large batch, Not for Human Use fill and finish services.
- Supply Chain And Sourcing Geographies
- Stevanato Group's supply chain includes manufacturing facilities in Europe, North America, and Asia. Key production sites are located in Piombino Dese and Latina in Italy, Bratislava in Slovakia, Monterrey in Mexico, and Zhangjiagang in China. They are also building a new plant in Sete Lagoas, Brazil. Significant investments are being made to expand capacity for high-value solutions in Fishers, Indiana (United States) and Latina, Italy, to meet rising global demand. The Fishers facility is intended to mirror the capabilities in Europe, particularly for EZ-fill technology, and to serve as a domestic supply chain for U.S. clients. They have also consolidated offices in Denmark and moved visual inspection activities to Italy, acquiring a new location in Bologna, Italy, to access strong technical talent.
- Sales Geographies And Expansion Plans
- Stevanato Group sells its products globally. The company has a global footprint which provides supply chain security to its customers. Specific regions mentioned for growth and customer engagement include the United States, Europe, and APAC (Asia-Pacific) for biosimilars. The investments in Fishers, Indiana, are aimed at serving the domestic United States market, while Latina, Italy, serves regional and national customers. The company is focused on expanding its presence in the broader global market for injectable biologics and biosimilars.
- How Key Themes May Help/Hurt
- Stevanato Group is strongly positioned to benefit from the 'MedTech Long '26: Life Science Tools & Bioprocessing' theme. The robust demand for biologics and GLP-1 therapeutics directly drives demand for their specialized bioprocessing consumables, advanced fill-finish capacity, and high-value drug delivery systems, especially for self-administration and ready-to-use platforms. The biotech funding recovery and R&D pipeline expansion will increase demand for their containment and delivery solutions for new drugs. Pharma reshoring, particularly in the US, and CDMO outsourcing for supply chain resilience also directly benefit Stevanato Group through increased investment in bioprocessing and specialized packaging. The revised EU GMP Annex 1 regulations are expected to accelerate ready-to-use adoption, which is a tailwind for STVN. However, persistent geopolitical tensions and a slower-than-anticipated economic recovery in China could hurt global demand. Lagging translation of funding to spending and budgetary constraints could also temper growth. Normalization of high-growth segments like GLP-1s, while still positive, means a slower growth rate compared to previous surges.
3 Main Long-Term Bull Details
- Robust Demand for High-Value Solutions (HVS) in Biologics and GLP-1s: Stevanato Group continues to see strong, sustained growth in its HVS portfolio, driven by ongoing demand for pre-fillable syringes and increasing prospects for cartridges, especially for GLP-1s (21-22% of Q1 revenue, >20% growth) and other biologics like monoclonal antibodies. This diversifies growth drivers and positions the company in high-growth therapeutic areas.
- Strategic Capacity Expansions and Operational Flexibility: The company's significant capital investments in its Fishers (US) and Latina (Italy) facilities are effectively ramping up, with commercial production at Fishers expected by end of 2026 or early 2027, and new RTU cartridge lines in Latina launching early 2027. The agile conversion of an underutilized vial line to a cartridge line in Piombino Dese further demonstrates operational flexibility to meet surging demand.
- Integrated End-to-End Solutions and Market Leadership in Injectables: Stevanato Group offers a unique integrated model, providing both drug containment/delivery solutions and the specialized machinery to produce them. This 'one-stop-shop' approach, combined with market leadership in areas like pre-sterilized vials and syringes, creates strong customer stickiness, raises barriers to entry, and allows them to support customers across the entire drug lifecycle, particularly for the growing injectable biologics market.
3 Main Long-Term Bear Details
- Slower-than-Expected Recovery in the Engineering Segment: The Engineering segment continues to underperform, with revenue declining 31% in Q1 2026. Despite initial margin improvements from optimization efforts, slower order intake, longer sales cycles due to more disciplined customer procurement, and a low backlog are delaying its return to historical performance, acting as a drag on overall company growth and profitability.
- Foreign Currency Headwinds and Tariff Costs: Foreign currency translation is expected to remain a headwind, with an anticipated impact of approximately EUR 18 million on revenue for fiscal 2026, partially affecting margins. Additionally, higher depreciation related to the ramp-up of new facilities in Fishers and Latina, along with temporary tariffs (EUR 1.7 million impact in Q1), continue to exert pressure on gross profit margins.
- Potential Market Shifts and Lengthening Sales Cycles: While GLP-1s remain a significant tailwind, their growth is normalizing to an expected mid-teens in 2026. Although management views oral GLP-1s as market expansion rather than cannibalization, the evolving market dynamics, coupled with lengthening sales cycles across the industry due to stricter CapEx committees, introduce potential uncertainties and slower decision-making for customers.
- Competitors And Differentiation
- Stevanato Group is a critical supplier alongside West Pharmaceutical (WST) in high-performance drug delivery systems, pre-fillable syringes, and containment vials. The company differentiates itself through its integrated model, providing both drug containment/delivery solutions and the specialized machinery to produce them. This 'one-stop-shop' approach, combined with market leadership in areas like pre-sterilized vials and syringes, creates strong customer stickiness, raises barriers to entry, and allows them to support customers across the entire drug lifecycle. They aim to be #1 or #2 in their core product categories within the injectables market and are progressively de-emphasizing non-core products in favor of more accretive solutions. The sales cycle has lengthened across the industry, with more disciplined procurement and higher hurdles with CapEx committees, a trend observed among peers, suggesting competition on efficiency and cost.
- Recent Performance & What The Market'S Focused On
- Stevanato Group started fiscal 2026 with solid momentum in the first quarter, delivering results largely in line with expectations. Total revenue grew 10% on a constant currency basis and 7% on a reported basis to EUR 273.6 million. This was driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw 13% reported growth, particularly from high-value solutions (up 17%) and syringes (up over 20%). GLP-1s accounted for 21-22% of total revenue and grew over 20% year-over-year. However, the Engineering segment experienced a 31% revenue decline, though it showed initial margin improvement due to optimization efforts. The market is focused on the continued strong demand for high-value solutions and GLP-1s, the successful ramp-up of new capacity in Fishers and Latina, and the ability to convert an underutilized vial line to a cartridge line to meet surging demand. Concerns remain around the slow order intake and low backlog in the Engineering segment, as well as the impact of foreign currency headwinds and higher depreciation on margins. Management reiterated its 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, expecting a stronger second half of the year.
- Revenue Segments And Estimated Mix
- Biopharmaceutical and Diagnostic Solutions (BDS) — Mix: 91%; Source: Q1 2026 transcript; Trend: 13% reported growth in Q1 2026
- Engineering — Mix: 9%; Source: Q1 2026 transcript; Trend: -31% reported decline in Q1 2026
- High-Value Solutions (within total revenue) — Mix: 47%; Source: Q1 2026 transcript; Trend: 17% growth in Q1 2026; expected 47-48% for FY26
- GLP-1s (product category within total revenue) — Mix: 21-22%; Source: Q1 2026 transcript; Trend: >20% growth in Q1 2026; expected mid-teens growth for FY26
- Syringes (within BDS) — Mix: n/m; Source: Q1 2026 transcript; Trend: >20% growth year-over-year in Q1 2026
- Other Containment and Delivery Solutions (within BDS) — Mix: n/m; Source: Q1 2026 transcript; Trend: 9% growth in Q1 2026
- Product Brands
- Nexa
- Alba
- EZ-fill
- Alina
- Vertiva
- Fina
- MAVIS
- Ompi
- Balda
- Spami
- Optrel
- InnoScan
- SVM
Bull / Bear DetailsStevanato Group remains a compelling investment as of 2026-07-26, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solut
Thesis
Stevanato Group remains a compelling investment as of 2026-07-26, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly for biologics and GLP-1s. Strategic capacity expansions are ramping up, supporting future growth and margin expansion. While the Engineering segment faces continued near-term challenges and currency headwinds persist, strong execution in high-value products and market tailwinds position STVN for sustained long-term growth.
Bull case
Stevanato Group continues to demonstrate strong growth in high-value solutions (HVS), which accounted for 47% of total revenue and grew 17% year-over-year in Q1 2026. This is fueled by ongoing demand for pre-fillable syringes and increasing prospects for cartridges, especially for GLP-1s (21-22% of Q1 revenue, >20% growth) and other biologics like monoclonal antibodies, diversifying growth drivers.
The company's significant capital investments in its Fishers (US) and Latina (Italy) facilities are effectively ramping up, with commercial production at Fishers expected by end of 2026 or early 2027, and new RTU cartridge lines in Latina launching early 2027. The agile conversion of an underutilized vial line to a cartridge line in Piombino Dese further demonstrates operational flexibility to meet surging demand.
Stevanato Group is well-positioned as a global leader in cartridges and benefits from strong secular tailwinds in injectable biologics, biosimilars, and self-administration. Annex 1 regulations are expected to accelerate ready-to-use adoption, and the company's ability to reconfigure assets efficiently in response to customer demand shifts strengthens its competitive advantage and market leadership.
Bear case
The Engineering segment continues to underperform, with revenue declining 31% in Q1 2026. Despite initial margin improvements from optimization efforts, slower order intake, longer sales cycles due to more disciplined customer procurement, and a low backlog are delaying its return to historical performance, acting as a drag on overall company growth and profitability.
Foreign currency translation is expected to remain a headwind, with an anticipated impact of approximately EUR 18 million on revenue for fiscal 2026, partially affecting margins. Additionally, higher depreciation related to the ramp-up of new facilities in Fishers and Latina, along with temporary tariffs (EUR 1.7 million impact in Q1), continue to exert pressure on gross profit margins.
While GLP-1s remain a significant tailwind, their growth is normalizing to an expected mid-teens in 2026, following higher growth rates in prior periods. Although management views oral GLP-1s as market expansion rather than cannibalization, the evolving market dynamics, coupled with lengthening sales cycles across the industry due to stricter CapEx committees, introduce potential uncertainties and slower decision-making for customers.
Bull / Bear Case
- Bear Case
- The Engineering segment remains a significant drag on overall performance, with revenue declining 31% in Q1 2026. Despite optimization efforts, slow order intake, lengthened sales cycles due to more disciplined customer procurement, and a low backlog are delaying its return to historical profitability. Foreign currency translation is a notable headwind, with an anticipated EUR 18 million impact on 2026 revenue, partially affecting margins. Additionally, higher depreciation costs related to the ramp-up of new facilities in Fishers and Latina, along with temporary tariffs (EUR 1.7 million impact in Q1 2026), continue to exert pressure on gross profit margins. While GLP-1 growth is strong, its normalization to mid-teens in 2026, coupled with evolving market dynamics and stricter CapEx committees, introduces potential uncertainties.
- Bull Case
- Stevanato Group is poised for sustained growth, driven by robust demand for high-value solutions (HVS) in its Biopharmaceutical and Diagnostic Solutions (BDS) segment. HVS accounted for 47% of Q1 2026 revenue and grew 17% year-over-year, fueled by GLP-1s (21-22% of revenue, >20% growth) and other biologics like monoclonal antibodies. Strategic capacity expansions in Fishers (US) and Latina (Italy) are ramping up, with new RTU cartridge lines launching in early 2027 and Fishers commercial production by early 2027. The agile conversion of a vial line to a cartridge line in Piombino Dese demonstrates operational flexibility. The company benefits from strong secular tailwinds in injectable biologics, biosimilars, and self-administration, with Annex 1 regulations accelerating ready-to-use adoption, solidifying its market leadership in cartridges.
- More Compelling & Why
- Bear. Stevanato Group's current EV/EBITDA multiple of approximately 19x-24x appears stretched given the persistent underperformance and revenue decline (31% in Q1 2026) of its Engineering segment, which acts as a significant drag on overall profitability and free cash flow generation (FCF yield of 0.05%-0.17%). The strongest argument for the bear case is the unresolved operational challenges and slow order intake in the Engineering segment, coupled with high capital expenditures for growth that suppress near-term free cash flow. My view would flip to bullish upon clear evidence of a sustained turnaround in the Engineering segment, demonstrated by consistent positive order intake growth and a significant improvement in FCF yield, indicating that growth investments are translating into robust cash generation.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| High-Value Solutions (HVS) Revenue Contribution and Growth | HVS are the primary driver of Stevanato Group's revenue growth and margin expansion, reflecting its strategic shift towards premium offerings in biologics and self-administration. Consistent performance above guidance indicates successful execution and market leadership. | HVS revenue as a percentage of total revenue (2026 guidance: 47-48%) and its year-over-year growth rate in subsequent quarters. Q1 2026 HVS revenue was 47% of total, growing 17% Y/Y. | Bullish: HVS revenue consistently at or above 48% of total revenue and Y/Y growth exceeding 17% (Q1 2026 rate). Bearish: HVS revenue falling below 47% of total revenue or significant deceleration in Y/Y growth below 17%. | Company earnings reports and conference call transcripts (Q2, Q3, Q4 2026). | Industry reports on biologics market growth or ready-to-use packaging adoption. | EvaluatePharma: Biologics market size and growth forecasts. |
| Engineering Segment Order Intake and Backlog Rebuild | The Engineering segment's underperformance due to slow order intake and low backlog is a drag on overall company growth and profitability. A turnaround is critical for the company's full potential and improved financial performance. | Management commentary on new order intake, backlog conversion rates, and pipeline strength in the Engineering segment. Watch for Y/Y revenue decline moderating faster than the mid-single to low double-digit guidance for 2026. | Bullish: Management reports a significant increase in new order intake, a faster-than-expected rebuild of the backlog, or a moderation of revenue decline beyond the guided range. Bearish: Continued slow order intake, further delays in converting pipeline to orders, or revenue decline at the higher end of the guidance range. | Company earnings reports and conference call transcripts (Q2, Q3, Q4 2026). | Industry news on capital expenditure trends in pharmaceutical manufacturing. | Industrial Info Resources: Pharmaceutical capital project tracking. |
| Commercial Production of Converted RTU Cartridge Line (Piombino Dese) | This conversion addresses immediate, strong demand for cartridges, bridging a capacity gap and demonstrating the company's agility in optimizing capital investments to meet customer needs in a high-growth area, enhancing market share. | Confirmation that the converted ready-to-use (RTU) cartridge line at the Piombino Dese facility has come into commercial production. Expected to begin in the coming weeks from May 7, 2026, implying by end of Q2 2026. | Bullish: Commercial production begins as expected by the end of Q2 2026, or earlier, successfully meeting customer demand. Bearish: Delays in bringing the converted RTU cartridge line into commercial production beyond Q2 2026. | Company press releases, SEC filings (earnings transcripts, Q2 2026 report). | Local news or industry publications covering manufacturing updates in Piombino Dese, Italy. | Supply chain intelligence platforms tracking manufacturing facility operational status. |
| Commercial Production Start at Fishers Facility | This milestone is crucial for Stevanato Group's revenue growth in high-value solutions and its strategic positioning in the growing market for integrated drug delivery systems, particularly for biologics and GLP-1s, and establishing domestic supply in the U.S. | Confirmation of commercial production beginning at the Fishers, Indiana facility, specifically for the first device program. Expected timeline is end of 2026 or early 2027. | Bullish: Commercial production begins at the end of 2026 or earlier, or with higher initial volumes than anticipated. Bearish: Delays in the start of commercial production beyond early 2027. | Company press releases, SEC filings (20-F, earnings transcripts), future earnings calls. | Industry news outlets covering pharmaceutical manufacturing investments in the US. | Thinknum: Job postings for Fishers facility (indicating ramp-up progress). |
| GLP-1 Revenue Growth Rate | GLP-1s are a significant tailwind, driving a substantial portion of biologics growth and overall revenue. Sustained high growth confirms the company's ability to capitalize on this high-demand therapeutic area and meet its guidance. | The year-over-year growth rate of GLP-1 revenue in subsequent quarterly reports. Management guided for mid-teens growth for 2026, after Q1 2026 GLP-1s accounted for 21-22% of total revenue. | Bullish: GLP-1 revenue growth exceeding mid-teens in 2026. Bearish: GLP-1 revenue growth falling below mid-teens in 2026. | Company earnings reports and conference call transcripts (Q2, Q3, Q4 2026). | Google Trends: Search volume for 'GLP-1 drugs' or specific drug names (e.g., 'Ozempic,' 'Wegovy') as a proxy for market interest. | IQVIA: GLP-1 drug sales data (global/regional). |
Key Reported Metrics, Reratings Triggers & ResultsThis is the primary driver of Stevanato Group's revenue growth and margin expansion, reflecting its strategic shift towards premium offerings in biologics and s
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| High-Value Solutions Revenue | 17% | This is the primary driver of Stevanato Group's revenue growth and margin expansion, reflecting its strategic shift towards premium offerings in biologics and self-administration. Continued strong performance indicates successful execution of its strategy. | Stevanato Group's High-Value Solutions Revenue needs to consistently represent above 48% of total revenue, exceeding the high end of its 2026 guidance (47-48%). Concurrently, year-over-year growth of High-Value Solutions Revenue must re-accelerate significantly from Q1 2026's 17%, ideally reaching or exceeding 30% year-over-year, aligning with or surpassing peer performance. | Hitting these thresholds validates Stevanato's strategic shift towards premium integrated solutions, demonstrating sustained execution in high-growth biologics and self-administration markets. This signals continued margin expansion and strengthens its competitive position, driving a positive re-evaluation of its long-term valuation. | ||||
| GLP-1 Revenue Growth | >20% | GLP-1s are a significant tailwind, and this metric is crucial for understanding the company's ability to capitalize on this high-growth therapeutic area and its impact on overall performance. Investors watch for sustained growth and market share. | Stevanato Group's GLP-1 Revenue Growth needs to exceed its reiterated 2026 guidance of mid-teens (e.g., 18-20% or higher). The company reported over 50% GLP-1 growth in 2025, which management described as an "initial surge". For 2026, they expect a normalization to mid-teens growth. A peer, West Pharmaceutical Services, expects GLP-1 and non-GLP-1 high-value product components to grow in the high teens organically for the full year 2026. Therefore, surpassing Stevanato's own mid-teens guidance would be a positive surprise against current market expectations. | Exceeding the mid-teens GLP-1 revenue growth target would signal stronger-than-anticipated execution in a critical high-growth area. This would validate Stevanato's ability to capitalize on robust demand for biologics and GLP-1s, mitigating concerns about growth normalization and competitive dynamics, thereby justifying a higher valuation and improved competitive positioning. | ||||
| Engineering Segment Revenue | -31% | This segment has been a drag on overall performance. Improvement in order intake, backlog, and revenue trend is crucial for the company's overall growth and profitability, signaling a successful turnaround of optimization efforts. | ||||||
Key QuestionsWill Stevanato Group achieve its mid-teens GLP-1 revenue growth target for 2026 and maintain High-Value Solutions at 47-48% of total revenue, and will oral GLP-
Will Stevanato Group achieve its mid-teens GLP-1 revenue growth target for 2026 and maintain High-Value Solutions at 47-48% of total revenue, and will oral GLP-1 therapies expand the market without significant cannibalization of injectables?
- Question 2
Can the Engineering segment demonstrate a tangible improvement in new order intake and backlog conversion in the second half of 2026, moderating its revenue decline faster than the mid-single to low double-digit expectation?
- Question 3
How quickly will the newly converted RTU cartridge line in Piombino Dese come into commercial production and contribute to revenue, and how will the combined ramp-up of this and other new capacities (Latina, Fishers) impact overall gross profit margins given depreciation and currency headwinds?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Scaling and executing growth investments: Management is focused on leveraging strategic growth investments in facilities like Latina and Fishers to expand capacity for high-value solutions (e.g., syringes, cartridges) and ensure successful customer validations and commercial production ramp-up. 2. Optimizing the Engineering Segment: Management is dedicated to improving the Engineering segment's performance through optimization efforts, rightsizing operations, streamlining processes, and strengthening sales and marketing to drive growth and return to historical performance levels. 3. Capitalizing on the GLP-1 and broader biologics market: A significant focus is on maintaining and expanding their leadership in the GLP-1 market and increasing participation in other injectable biologics with their premium high-value product portfolio, including cartridges for large volume biologics. | The overall takeaway from the call is one of cautious optimism. Stevanato Group delivered solid Q1 2026 financial results, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly from high-value solutions and GLP-1s, supported by capacity ramp-up in Latina and Fishers. While the Engineering segment showed initial margin improvement due to optimization efforts, it remains a concern due to slow order intake and a low backlog. Management expressed confidence in the long-term growth trajectory of biologics and GLP-1s but acknowledged ongoing challenges in the Engineering segment and anticipated currency headwinds. | Total Revenue: 5% (reported); Biopharmaceutical and Diagnostic Solutions (BDS) Segment: 10% (reported); Engineering Segment: -23%; High-Value Solutions: 31%; Other Containment and Delivery Solutions (within BDS): -9% | 1. GLP-1 volume visibility and durability, and risk from orals: Analysts questioned the long-term outlook for GLP-1s and the potential impact of oral therapies. Management responded that they are positive on the GLP-1 outlook, reiterating mid-teens growth for 2026, largely covered by contractual commitments. They expect the market to continue to grow, with 70% still in injectables, and orals leading to market expansion rather than cannibalization. 2. Engineering segment recovery, order intake, and initiatives: Analysts pressed on the slower-than-anticipated order materialization in the Engineering segment. Management stated they are making progress on operational improvements and winning new contracts, expecting a stronger second half. They are focused on improving operational efficiency and increasing order intake, noting that sales cycles have lengthened due to slower customer decisions and more disciplined procurement. 3. BDS segment margins and factors impacting them: Analysts inquired about the moving parts in Q1 BDS margins and the outlook for the year. Management reiterated guidance for BDS gross profit margin to be in line or slightly better than last year, citing a better mix, but also headwinds from higher depreciation (especially in Q1), foreign currency (EUR 8 million impact on top line), and temporary tariffs (EUR 1.7 million impact). | Total Revenue: 7% (reported); Biopharmaceutical and Diagnostic Solutions (BDS) Segment: 13% (reported); Engineering Segment: -31%; High-Value Solutions: 17%; GLP1s (product category, within total revenue): >20%; Syringes (within BDS): >20%; Other Containment and Delivery Solutions (within BDS): 9% |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Scaling High-Value Solutions Capacity and Execution**: Management is focused on leveraging strategic growth investments in facilities like Latina and Fishers to expand capacity for high-value solutions (e.g., Nexa syringes, EZ-fill cartridges) and ensure successful customer validations and commercial production ramp-up. They emphasized running at "approximately full capacity" for prefilled syringes in 2025 and the continued positive momentum into 2026. 2. **Optimizing and Repositioning the Engineering Segment**: Management is dedicated to improving the Engineering segment's performance through optimization efforts, rightsizing operations, streamlining processes, and strengthening sales and marketing. While acknowledging slower order intake and a longer recovery than expected, they are focused on securing new, more standardized orders and leveraging operational improvements. 3. **Capitalizing on the GLP-1 and Broader Biologics Market**: A significant focus is on maintaining and expanding their leadership in the GLP-1 market, which was a major tailwind in 2025 and is expected to continue growing. Beyond GLP-1s, they are focused on increasing participation in other injectable biologics with their premium high-value product portfolio, aiming to be a key partner for all injection-based therapies. | The overall takeaway from the call is one of cautious optimism. Stevanato Group delivered solid financial results for Q4 and full-year 2025, driven by robust double-digit growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong performance in high-value solutions, particularly from GLP-1s. Management expressed confidence in their strategic execution, capacity expansions in Latina and Fishers, and their positioning in the growing biologics and self-administration markets. However, the tone was notably cautious regarding the Engineering segment, acknowledging that its recovery and order intake are taking longer than expected, despite operational improvements. Currency headwinds are also anticipated for 2026. The company provided 2026 guidance reflecting continued high-value growth but a more muted outlook for Engineering, with an expectation of modest margin expansion and breakeven to positive free cash flow. | For the third quarter of 2025: * Total revenue increased by 9% year-over-year. * Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. * Engineering segment declined by 19% year-over-year. * Revenue from high-value solutions grew 47%. * Revenue from other containment delivery solutions decreased by 10%. | 1. **GLP-1 Growth Outlook for 2026**: Analysts questioned why the 2026 GLP-1 growth guidance (mid-teens) seemed conservative after 50% growth in 2025. Management responded that 2025 saw a "massive preparation of the supply chain" and an "initial surge," and a mid-teens growth in 2026 is a "realistic number" as products go commercial, followed by a "period of normalization where growth slows a bit." They also noted that beyond 2026, the market configuration (originator vs. biosimilar, pen vs. auto-injector) is still evolving. 2. **Engineering Segment Recovery and Order Intake**: Analysts pressed on the disappointing 2026 guidance for the Engineering segment and the reasons behind the low order intake. Management explained that while operational progress is strong (e.g., doubled site acceptance rates), the sales cycle for these technical lines is longer than anticipated, leading to delayed order confirmations. They reiterated that the underlying pharmaceutical market demand for new machines, especially for biologics and self-administration, is "robust" and the "pipeline is healthy," with a strong medium-term outlook. 3. **High-Value Solutions Capacity vs. Demand and Margin Expansion**: Analysts inquired about the utilization and capacity constraints for high-value solutions, particularly with the ramp-up of Fishers and Latina, and the drivers of margin expansion for 2026. Management confirmed that they ran "approximately full capacity" in 2025 for prefilled syringes and expect robust demand to continue playing a role in 2026. For margins, they guided for 0-30 basis points expansion, citing headwinds from higher depreciation and currency, but tailwinds from improving financial performance at Latina and Fishers as they scale, and a better project mix in Engineering. | For the fourth quarter of 2025: * Total company revenue increased by 7% at constant currency and 5% on a reported basis. * Biopharmaceutical and Diagnostic Solutions (BDS) segment revenue increased by 13% at constant currency and 10% on a reported basis. * Engineering segment revenue decreased by 23%. * Revenue from high-value solutions grew 31%, representing approximately 49% of total company revenue. * Revenue from other containment and delivery solutions (within BDS) decreased by 9%. |
· 2025Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Executing Strategic Roadmap and Capacity Expansion**: Management is focused on leveraging and scaling up growth investments in capacity expansion to meet increased demand for high-value products, particularly Nexa syringes and EZ-fill vials and cartridges, across their Fishers and Latina facilities. 2. **Optimizing the Engineering Segment**: Management is actively working on a business optimization plan for the Engineering segment, strengthening the sales organization, refining commercial processes, and repositioning the segment for stronger profitability, acknowledging that it will take more time to return to historical performance levels. 3. **Meeting Demand for Injectable Biologics and Self-Administration**: The company is focused on meeting the demands of high-growth markets like injectable biologics, which require premium containment and delivery solutions, and supporting the increasing trend towards self-administration of medicine with products like EZ-fill cartridges. | The overall takeaway from the call is one of cautious optimism. The company delivered solid third-quarter financial results, exceeding expectations primarily driven by strong performance in the BDS segment and record growth in high-value solutions. Management reiterated its full-year 2025 guidance despite foreign currency headwinds and challenges in the Engineering segment, demonstrating confidence in their strategic roadmap and the ability of high-value solutions growth to offset these impacts. The tone was positive regarding the BDS segment, high-value solutions, and the long-term market tailwinds from biologics and self-administration. However, there was a cautious tone regarding the Engineering segment, acknowledging that its recovery will take more time than initially expected, despite ongoing optimization efforts. | For Q2 2025, the Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 10% year-over-year. The Engineering segment declined by 2% year-over-year in Q2 2025. | 1. **Q3 Outperformance and High-Value Solutions Growth**: Analysts inquired about the $10 million outperformance in Q3 and the drivers of strong high-value solutions growth. Management responded that the $10 million was an acceleration of Q4 sales to accommodate customer supply chain needs, primarily in high-value solutions like high-performance syringes. They attributed high-value growth to strong demand for Nexa syringes, traction in Alba syringes, and a recovery in sterile vials. 2. **Engineering Segment Recovery and Timeline**: Analysts pressed on the timeline for the Engineering segment's return to growth and whether it could grow in 2026. Management acknowledged that while operational progress is being made, converting the healthy pipeline into new orders has been slower than anticipated, mainly due to key customers awaiting final acceptance tests and reevaluating manufacturing footprints. They believe the long-term demand landscape remains strong due to industry expansion and technology upgrades. 3. **Biosimilar Opportunity, especially GLP-1s**: Analysts asked about the broader picture of biosimilars, specifically GLP-1s, and their contribution to Stevanato's growth. Management explained that biosimilars help enlarge revenue for the industry, and Stevanato is deeply involved with both originator and biosimilar programs across its high-value product platform, including Nexa syringes and ready-to-fill cartridges. They view this as a net positive effect, translating into more orders for their products. | Total revenue increased by 9% year-over-year. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. The Engineering segment declined by 19% year-over-year. Revenue from high-value solutions grew 47%. Revenue from other containment delivery solutions decreased by 10%. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| GLP1s accounted for approximately 21% to 22% of total company revenue in Q1 2026, driving a 15% increase in revenue from biologics. The market for GLPs and incretin therapies is expected to continue to grow and evolve over the next decade with novel indications beyond diabetes and obesity, new originators in clinical phases, and biosimilars gaining traction. Demand for cartridges is extending into many other traditional large pharma and emerging biotech players for biologics, including large volumes up to 20 ml for home-based subcutaneous injections. The company converted an underutilized ready-to-use vial line to a ready-to-use cartridge line in Piombino Dese and is preparing for the next phase of expansion for EZ-fill cartridges in Latina with new RTU 400 lines. Annex 1 regulations are seen as a longer-term accelerator for ready-to-use adoption. The market opportunity for GLP-1s is vast, with over 150 million potential patients in the U.S. and 1.5 billion globally. A new service offering for large batch, Not for Human Use fill and finish services has been launched. | The company anticipates continued benefits as more originators and biosimilars enter the GLP-1 market. Stevanato Group aims to be #1 or #2 in its core product categories within the injectables market and is progressively de-emphasizing non-core products in favor of more accretive solutions. The sales cycle has lengthened, and decision cycles are slower across the industry, with more disciplined procurement and higher hurdles with CapEx committees, a trend observed among peers. | The industry is seeing a shift towards home-based subcutaneous injections for biologics, driven by higher drug potency. Annex 1 regulations are driving higher standards for contamination control and quality risk management, accelerating ready-to-use adoption. The injectable biologics market is expected to see strong growth, fueled by biosimilars, monoclonal antibodies, and other advanced therapies. Inflationary pressures, including gas prices, energy, logistics, and supplier costs, are impacting the industry, with companies working to mitigate these effects through price adjustments with customers. | Commercial production at the Fishers facility is expected to begin at the end of 2026 or early 2027. Commercial production of RTU cartridges on the new Latina line is set to launch in early 2027. The company is maintaining its 2026 guidance for revenue (EUR 1.260 billion to EUR 1.290 billion), adjusted EBITDA (EUR 331.8 million to EUR 346.9 million), and adjusted diluted EPS (EUR 0.59 to EUR 0.63). The second half of 2026 is expected to be stronger than the first half. The GLP-1 market is projected to continue growing for several years with predictable volumes for 2026. The Engineering segment anticipates a stronger second half of the year, with an expected decline of mid-single digits to low double digits compared to 2025. BDS gross profit margin for the year is expected to be in line with or slightly better than last year, and high-value solutions are projected to represent 47% to 48% of total revenue for the year. | Life | Onshoring manufacturing (U.S. as a strategic hub for domestic supply). | We started fiscal 2026 with strong momentum in the first quarter, highlighted by 10% revenue growth on a constant currency basis. The market for GLPs and incretin therapies is expected to continue to grow and evolve over the next decade. We are confident that we will continue benefiting in the future as more originators and biosimilars enter the market. We believe that we are well positioned to support our customers and to continue capitalizing on the rising growth in biologics and injectable therapies. | customer orders are materializing slower than expected. we still have work to do to secure new orders and rebuild the backlog to drive sustainable improvements in the segment's financial performance. we remain somewhat cautious due to the low backlog and the time required to get new orders over the finish line. The sales cycle overall has lengthened. And perhaps it's really the decision cycle. As expected, the biggest factor was higher depreciation related to the ramp-up in Fishers and Latina. the headwind from foreign currency. the impact of tariffs, some of which are expected to be recover in future periods. | The company is strengthening its commercial organization with new talent in the U.S. and Europe for the Engineering segment. The U.S. team is expanding as the Fishers facility builds its presence as a strategic hub for domestic supply. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (approximately 46-47% growth) and a shift to ready-to-use platforms that support self-administration; GLP-1 biosimilar activity and broader biologics demand supported by ready-to-use cartridges and autoinjector formats; accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); ongoing capital investments at Fishers and Latina to scale Nexa, EZ-fill and related lines, with continued growth expected through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on biosimilars' growing role and the need for integrated, high-value packaging and delivery solutions. Biosimilars can broaden revenue across originator and biosimilar programs (roughly 70% originator, 30% biosimilar when patents expire), and management emphasized maintaining leadership across Nexa, Alba and EZ-fill platforms. The company noted currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The ambition to become a fully integrated high-value solutions provider suggests differentiation but also intensifies competition with peers expanding into end-to-end systems (e.g., larger players in packaging and devices). | Industry trends include robust growth in injectable biologics, a shift toward ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). Onshoring of manufacturing toward the United States is accelerating as customers reassess footprints. Major capacity investments at Fishers and Latina to support biologics and auto-injector ecosystems, plus new lines and clean rooms for Alina Pen and broader CMO initiatives, indicate a multi-year capacity build and increased focus on high-value biologics packaging and devices; sustainability ESG milestones are also part of industry evolution. | Outlook remains constructive: 2026 guidance centers High-Value Solutions at 47-48% of revenue; currency headwinds expected but offset by organic growth; continued capacity ramp at Fisher and Latina to sustain longer-term growth toward 2028; investments in EZ-fill, Nexa, Alba, and ready-to-fill cartridges, plus the new Germany clean room for Alina Pen; potential upside from broader CMO initiatives and expanded biologics applications. | GLP1 | Biologics growth, ready-to-use platforms, self-administration, onshoring manufacturing, and end-to-end integration in packaging and devices; regulatory tightening and tariff headwinds; biosimilars expansion; capacity expansion across US and Europe. | We remain on track to meet our 2025 guidance. The industry expands its capacity to satisfy growing demand for injectable biologics and devices. EZ-fill cartridges are setting a new standard. We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind. Certain tariff costs were not mitigated. The current slowdown in order flow is not permanent and will take time to recover. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems. | Industry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones). | Prospects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond. | GLP1 | We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time. | Strengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems. | Industry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones). | Prospects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond. | GLP1 | We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time. | Strengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-03-04 | Stevanato Group reported solid Q4 and FY25 results, driven by strong double-digit growth in high-value solutions, particularly Nexa syringes for GLP-1s. The company provided positive 2026 guidance, forecasting mid-teens GLP-1 growth and continued BDS segment strength, despite ongoing Engineering segment challenges. The stock's 4.62% rise, significantly outperforming the SPY, indicates the market perceived the results and outlook positively, aligning with the company's strategic focus on high-growth biologics. | Other | Bullish | +4.62% (vs SPY: +5.79%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| STVN_18398d39 | early 2027 | 2027-01-01 | 2027-03-31 | Launch of commercial production of RTU cartridges on the new RTU 400 EZ-fill cartridge lines at Latina. | This expansion will bring much-needed capacity for high-speed, high-output ready-to-use cartridges, addressing rising global demand and driving operational efficiency and revenue growth for Stevanato Group. | Ticker | 2026-05-07 | earnings_transcript |
| STVN_bc850de3 | at the end of 2026 or early 2027 | 2026-10-01 | 2027-03-31 | Commencement of commercial activities for contract manufacturing of large device programs at the Fishers facility. | This represents a new revenue stream and leverages the company's capabilities in drug delivery devices, contributing to overall growth and diversification. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_90225f22 | the GLP-1 in the next decade, it will continue to be a powerful tailwinds | 2027-01-01 | 2036-12-31 | The evolving landscape of the GLP-1 market, including the mix of injectables vs. orals, originator vs. biosimilar strategies, and new product launches. | This evolution will determine the long-term demand trajectory for Stevanato's high-value syringes, cartridges, and devices, impacting its sustained growth and market leadership in this critical therapeutic area. | Theme | 2026-03-04 | earnings_transcript |
| STVN_ced6ef02 | commercial activities to begin at the end of 2026 or early 2027 for the first device program | 2026-10-01 | 2027-03-31 | Commencement of commercial activities for the first large device program at the Fishers facility for a key U.S. customer. | This represents a new significant revenue stream from contract manufacturing activities, leveraging integrated capabilities and high-value solutions for a major client. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_ca09a557 | at the end of 2028 | 2028-10-01 | 2028-12-31 | Fishers facility reaching full production capacity and generating $0.5 billion in revenue. | Achieving full capacity at Fishers will significantly boost high-value solution revenue, improve overall company margins, and validate the strategic investment in the facility. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_2673ce4f | mid-teens growth for 2026 | 2026-01-01 | 2026-12-31 | Stevanato Group achieving mid-teens revenue growth from GLP-1 related products in fiscal year 2026. | GLP-1s are a significant revenue driver (19-20% of 2025 revenue), and achieving this growth is crucial for overall company performance and investor sentiment. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_ebb2649b | Preparations are underway for the next phase of EZ-fill cartridge production to meet the rising demand for ready-to-use cartridges. This next phase will be powered by our new R400 EZ-fill cartridge lines. | 2026-01-01 | 2026-12-31 | Ramp-up of the next phase of EZ-fill cartridge production at the Latina facility, utilizing new R400 EZ-fill cartridge lines. | This expansion directly addresses rising demand for ready-to-use cartridges, a high-value solution, contributing to revenue growth and strengthening the company's position in the self-administration market. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_b86df9cd | line installations and customer validation activities are expected to continue all year | 2026-01-01 | 2026-12-31 | Continued progress and successful completion of line installations and customer validation activities at the Fishers facility throughout 2026. | This is essential for ramping up capacity for high-value syringes and other products in the US, meeting customer demand, and improving the facility's financial performance. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_7fce4c2f | this year, we're going to install the first high-speed line forecast is way to fill, but the goal is to do the validation is yet to start to do commercial revenue in the beginning of 2027 | 2026-03-07 | 2027-03-31 | Successful installation, validation, and commencement of commercial revenue generation from new high-speed EZ-fill cartridge lines at the Latina facility. | This expansion is critical to meet rising global demand for cartridges, support new pen injector formats and biosimilars, and drive future high-value solutions growth and margin expansion. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_5a8f34f7 | continue into 2026 | 2026-01-01 | 2026-12-31 | Continued scaling of commercial production for Nexa Syringes at the Latina facility. | Increased production capacity for high-demand Nexa syringes will drive revenue growth in high-value solutions and improve operating leverage at the Latina plant. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_d69cac2b | throughout 2026 | 2026-01-01 | 2026-12-31 | Continued installation and customer validation of additional syringe lines at the Fishers facility. | This will increase capacity for high-value solutions, driving revenue growth and margin expansion as the facility scales and gains operating leverage. | Ticker | 2025-11-07 | earnings_transcript |